Could crowd funding be a solution to the financing struggles of young biotech companies in the early stages of drug development? Clive Cookson talks to Andrew Ward about the benefits and pitfalls of this new model for financing medical science.

iTunes Stitcher audioBoom SoundCloud Overcast RSS


Copyright The Financial Times Limited 2017. All rights reserved.
myFT

Follow the topics related to this show

Comments have not been enabled for this podcast.